Kanimoto Y, Suzuki Y, Miwa Y, Akino H, Isomatu Y, Okada K
Department of Urology, Fukui Medical School.
Hinyokika Kiyo. 1991 Mar;37(3):229-33.
Inhibition of thymidylate synthase (TS) and the concentration of tegafur, 5-FU and uracil in the tumor and the non-tumor tissues were compared in 18 uroepithelial cancer patients who had been administered UFT (600 mg/day) for seven days before operation. 5-FU and uracil levels in the tumor tissue were increased to 5.1 and 3.6 fold, respectively, compared those in the normal tissue, although there was no difference in tegafur levels between normal and tumor tissue. The mean inhibition rate of TS activity in the tumor tissue was significantly higher (36%) than that in the normal tissue (21%). However, no correlation between 5-FU level and inhibition rate of TS activity was found in either tissue. Not only the higher tumor concentration of 5-FU but also the higher inhibition of TS activity in the tumor tissue suggests that UFT is likely a useful drug for the treatment of uroepithelial carcinomas.
在18例术前接受7天UFT(600毫克/天)治疗的尿路上皮癌患者中,比较了胸苷酸合成酶(TS)的抑制情况以及肿瘤组织和非肿瘤组织中替加氟、5-氟尿嘧啶(5-FU)和尿嘧啶的浓度。肿瘤组织中的5-FU和尿嘧啶水平分别比正常组织增加了5.1倍和3.6倍,尽管正常组织和肿瘤组织中的替加氟水平没有差异。肿瘤组织中TS活性的平均抑制率(36%)显著高于正常组织(21%)。然而,在任何一种组织中,均未发现5-FU水平与TS活性抑制率之间存在相关性。肿瘤组织中5-FU浓度较高以及TS活性抑制较高,这两者均表明UFT可能是治疗尿路上皮癌的一种有效药物。